The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | The value of treating MGUS and smoldering myeloma patients with novel immunotherapies
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, briefly explains the importance of using the best available drugs at an earlier stage instead of waiting until disease progression. Dr Ghobrial also highlights the excitement around immunotherapies, including CAR-T therapy and antibodies, for the treatment of patients with smoldering myeloma and monoclonal gammopathy of undetermined significance (MGUS). This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
